Pulmonary Disorders and COVID-19: Difference between revisions

Jump to navigation Jump to search
Line 22: Line 22:


===Increased mortality in COPD patients===
===Increased mortality in COPD patients===
*According to a study conducted in China, having an underlying comorbidity such as chronic obstructive pulmonary disease (COPD) conferred a mortality hazard ratio of 2.681, even after adjusting for smoking status.
*According to a [[Study design|study]] [[Conduct|conducted]] in China, having an [[Underlying representation|underlying]] [[comorbidity]] such as [[chronic obstructive pulmonary disease]] ([[Chronic obstructive pulmonary disease|COPD]]) conferred a [[mortality]] [[hazard ratio]] of 2.681, even after adjusting for [[smoking]] status.


==References==
==References==
<references />
<references />

Revision as of 16:01, 18 June 2020

To go to the COVID-19 project topics list, click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]

Overview

Covid-19 infection is associated with pulmonary complications such as acute respiratory distress syndrome, pneumonia, pulmonary embolism, hypoxemia, superinfection, respiratory failure, and increased mortality in patients with an underlying pulmonary disease such as chronic obstructive pulmonary disease (COPD).

Complications

Acute respiratory distress syndrome

Pneumonia

Pulmonary embolism

Hypoxemia

Superinfection

Respiratory failure

Increased mortality in COPD patients

References